In 2015, the American College of Medical Genetics and Genomics (ACMG) in collaboration with the Association of Molecular Pathologists (AMP) published guidelines for the interpretation and classification of germline genomic variants. The ACMG terminology guidelines outlined criteria for assigning one of five categories: benign, likely benign, uncertain significance, likely pathogenic and pathogenic. While the paper laid out 28 different classifiers and the justification for them, it did not provide specific algorithms for implementing these classifiers in an automated manner. Here we present the Bitscopic Interpreting ACMG Standards 2015 (BIAS-2015) software as a complete, open-source algorithm which categorizes variants according to the ACMG classification system. BIAS-2015 evaluates 18 of the 28 ACMG criteria to classify variants in an automated and consistent way while recording the rationale for each classifier to enable in-depth review. We used the genomic data from the ClinGen Evidence Repository (eRepo v1.0.29), one of two FDA-recognized human genetic variant databases, to evaluate the performance of the BIAS-2015 algorithm. All code for BIAS-2015 has been made available on GitHub.

The authors have declared no competing interest.

Bitscopic internal funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes